Menu
Not yet recruiting NCT06920069

Study of Concomitant Administration of the sIPV and DTaP or MMR

Phase IV Interventional Polio Diphteria, Tetanus and Pertussis MMR Vaccine

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: sIPV, DTaP, bOPV 1,3, MMR Vaccine.
Who it may be relevant to
Registry conditions: Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine. Basic parameters: 2 months — 2 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Phase IV Study of Evaluating Immunogenicity and Safety of Concomitant Administration of Sabin-strain-based Inactivated Poliovirus Vaccine (Vero Cells) and Adsorbed Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine or Measles, Mumps and Rubella Combined Live-attenuated Vaccine

Overview

This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR in infants aged 2 months. Primary immunogenicity endpoints in all groups include the seroconversion rate of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies 30 days after basic immunization. Secondary immunogenicity endpoints include the seropositive rates, seroconversion rates, geometric mean titer/concentration (GMT/GMC), geometric mean fold increase (GMFI) of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies, and anti-measles, anti-mumps, and anti-rubella antibodies 30 days after full immunization. The secondary safety endpoints are the incidence of adverse events (AEs) within 30 minutes after each injection, the incidence of solicited local and systematic AEs in the period of solicitation after each injection, the incidence of unsolicited AEs in 30 days after each injection, the incidence of AEs in 30 days after each injection, and the incidence of serious adverse events in 6 months after administrations.

Detailed description

This is a randomized, open-labeled, parallel phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR. 2640 participants aged 2 months will be randomly assigned to 4 cohorts in a ratio of 1:1:1:1. \[Cohort A\] 660 infants will take administration of sIPV at 2, 3, 4, 18 months of age and DTaP at 2, 4, 6, and 18 months of age. sIPV and DTaP at 2, 4, and 18 months of age will be taken concomitantly. \[Cohort B\] 660 infants will take administration of sIPV at 2, 3 months of age, bOPV at 4 months and 4 years of age, and DTaP at 2, 4, 6, 18 months of age. sIPV/bOPV at 2, 4 months of age will be taken concomitantly. \[Cohort C\] 660 infants will take administration of sIPV at 2, 3, 4, 18 months of age, DTaP at 2, 4, 6, and 18 months of age, and MMR at 18 months of age. DTaP will be taken 7 days after sIPV at 2, 4, 18 months of age. Half participants will take concomitant administration of sIPV and MMR at 18 months of age, and the rest will take them separately (MMR at 19 months of age). \[Cohort D\] 660 infants will take administration of sIPV at 2, 3 months of age, bOPV at 4 months and 4 years of age, and DTaP at 2, 4, 6, 18 months of age. DTaP will be taken 7 days after sIPV/bOPV at 2, 4 months of age.

For immunogenicity assessment, blood samples on Day 0 and Day 30 after basic immunization of each kind of investigational vaccine would be collected to evaluate the type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies, and anti-measles, anti-mumps, and anti-rubella antibodies for different groups.

For safety assessment, adverse events after each dose would be recorded through the diary and contact cards by participants' guardians to collect solicited or unsolicited AEs in periods of solicitation and nonsolicitation, respectively. From 31 days after the final dose to 6 months later, serious adverse events will be evaluated by the investigator via phone call or active reports by participants' guardians.

Interventions

  • Biological sIPV
    Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose
  • Biological DTaP
    Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose
  • Biological bOPV 1,3
    Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose
  • Biological MMR Vaccine
    Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose

Primary outcome measures

  • Immunogenicity index-seroconversion rate of type I anti-poliovirus neutrilizing antibody [Time frame: Between baseline and day 30 after basic vaccination]
  • Immunogenicity index-seroconversion rate of type II anti-poliovirus neutrilizing antibody [Time frame: Between baseline and day 30 after basic vaccination]
  • Immunogenicity index-seroconversion rate of type III anti-poliovirus neutrilizing antibody [Time frame: Between baseline and day 30 after basic vaccination]
  • Immunogenicity index-seroconversion rate of anti-DT antibody [Time frame: Between baseline and day 30 after basic vaccination]
  • Immunogenicity index-seroconversion rate of anti-TT antibody [Time frame: Between baseline and day 30 after basic vaccination]
  • Immunogenicity index-seroconversion rate of anti-PT antibody [Time frame: Between baseline and day 30 after basic vaccination]
  • Immunogenicity index-seroconversion rate of anti-FHA antibody [Time frame: Between baseline and day 30 after basic vaccination]
Secondary outcome measures (12)
  • Immunogenicity index-seropositive rate of type I anti-poliovirus neutrilizing antibody [Time frame: Day 30 after basic vaccination]
  • Immunogenicity index-seropositive rate of type I anti-poliovirus neutrilizing antibody [Time frame: Day 30 after full vaccination]
  • Immunogenicity index-seropositive rate of type II anti-poliovirus neutrilizing antibody [Time frame: Day 30 after basic vaccination]
  • Immunogenicity index-seropositive rate of type II anti-poliovirus neutrilizing antibody [Time frame: Day 30 after full vaccination]
  • Immunogenicity index-seropositive rate of type III anti-poliovirus neutrilizing antibody [Time frame: Day 30 after basic vaccination]
  • Immunogenicity index-seropositive rate of type III anti-poliovirus neutrilizing antibody [Time frame: Day 30 after full vaccination]
  • Immunogenicity index-geometric mean titer (GMT) of type I anti-poliovirus neutrilizing antibody [Time frame: Day 30 after basic vaccination]
  • Immunogenicity index-geometric mean titer (GMT) of type I anti-poliovirus neutrilizing antibody [Time frame: Day 30 after full vaccination]
  • Immunogenicity index-geometric mean titer (GMT) of type II anti-poliovirus neutrilizing antibody [Time frame: Day 30 after basic vaccination]
  • Immunogenicity index-geometric mean titer (GMT) of type II anti-poliovirus neutrilizing antibody [Time frame: Day 30 after full vaccination]
  • Immunogenicity index-geometric mean titer (GMT) of type III anti-poliovirus neutrilizing antibody [Time frame: Day 30 after basic vaccination]
  • Immunogenicity index-geometric mean titer (GMT) of type III anti-poliovirus neutrilizing antibody [Time frame: Day 30 after full vaccination]

Eligibility criteria

Inclusion criteria

  • Age Requirement: Infants aged 2 months at the time of enrollment
  • Provision of Legal Identification: Volunteers and their legal guardians or appointed representatives must provide valid legal identification documents.
  • Informed Consent: Legal guardians or appointed representatives of volunteers must have the capacity to understand the informed consent document and the research process, voluntarily participate, and sign the informed consent form.
  • Adherence: Legal guardians or appointed representatives of volunteers must be able to comply with the requirements in the study as well as complete relevant visits on time.
  • Birth Condition: Full-term at birth (gestational age ≥ 37 weeks and < 42 weeks) and birth weight ≥ 2500g

Exclusion criteria

  • Vaccination History: received vaccines containing diphtheria-tetanus-pertussis antigens, polio antigens, Hib conjugate vaccine, or 13-valent pneumococcal conjugate vaccine before enrollment.
  • Those who had received blood transfusions or used blood products (except hepatitis B immunoglobulin) before enrollment.
  • Recent Vaccination: Volunteers received any inactivated vaccines or subunit vaccines within 7 days (including the 7th day) prior to vaccination with the investigational vaccine, or any other live attenuated vaccines within 14 days (including the 14th day) prior to vaccination.
  • Acute Illness: Volunteers have experienced acute illnesses (e.g., fever) within 3 days before enrollment, or have used antipyretic analgesics or antihistamines within 3 days.
  • Allergic History: Volunteers who are allergic to any component of sIPV, bOPV, DTaP, or MMR, or who are allergic to kanamycin sulfate, kanamycin, or gentamicin sulfate, or those with an allergic constitution.
  • Birth Condition: Severe neonatal diseases caused by abnormal delivery and other reasons, such as birth trauma, neonatal asphyxia, respiratory distress syndrome, neonatal intracranial hemorrhage, etc., or patients with clinically confirmed severe hyperbilirubinemia.
  • Neurological and Mental Health: Volunteers with encephalopathy, convulsions, epilepsy, or other progressive neurological disorders, or those whose families have a history of genetic predisposition to convulsions or epilepsy, or a history of genetic predisposition to mental illness.
  • History of Related Illness: Volunteers who have a history of poliomyelitis, pertussis, diphtheria, tetanus, measles, rubella, or mumps.
  • Immune Therapy: Volunteers with immunodeficiency, weakened immune function, or those who have received immunosuppressive therapy (such as long-term systemic glucocorticoid treatment, but excluding local medications like inhalants or nasal sprays).
  • Other Diseases: Volunteers with severe diseases, encompassing those in the cardiovascular system, blood and lymphatic systems, immune system, kidneys, liver, gastrointestinal tract, respiratory system, metabolism, and bones, etc.
  • Participation in Other Clinical Studies: Volunteers are currently or have plans to participate in other clinical studies before enrollment.
  • Investigator's Discretion: The final exclusion criterion is the investigator's discretion to determine whether a volunteer is suitable for participation in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

China · 9 centers
  • Lufeng Center for Disease Control and Prevenion — Chuxiong
  • Yuanmou Center for Disease Control and Prevention — Chuxiong
  • Wuding Center for Disease Control and Prevention — Chuxiong
  • Yaoan Center for Disease Control and Prevention — Chuxiong
  • Lancang Center for Disease Control and Prevention — Puer
  • Yanshan Center for Disease Control and Prevention — Wenshan
  • Qiubei Center for Disease Control and Prevention — Wenshan
  • Guangnan Center for Disease Control and Prevention — Wenshan
  • … and 1 more center

Identifiers

NCT: NCT06920069 · sIPV-401

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗